Low expression of EXOSC2 protects against clinical COVID-19 and impedes SARS-CoV-2 replication

Tools

Moll, Tobias and Odon, Valerie and Harvey, Calum and Collins, Mark O and Peden, Andrew and Franklin, John and Graves, Emily and Marshall, Jack NG and dos Santos Souza, Cleide and Zhang, Sai and Castelli, Lydia and Hautbergue, Guillaume and Azzouz, Mimoun and Gordon, David and Krogan, Nevan and Ferraiuolo, Laura and Snyder, Michael P and Shaw, Pamela J and Rehwinkel, Jan and Cooper-Knock, Johnathan (2022) Low expression of EXOSC2 protects against clinical COVID-19 and impedes SARS-CoV-2 replication. Life Science Alliance, 6 (1). e202201449. (https://doi.org/10.26508/lsa.202201449)

[thumbnail of Moll-etal-LSA-2022-Low-expression-of-EXOSC2-protects-against-clinical-COVID-19-and-impedes]
Preview
 Text. Filename: Moll-etal-LSA-2022-Low-expression-of-EXOSC2-protects-against-clinical-COVID-19-and-impedes.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo
Download (1MB)| Preview

Abstract

New therapeutic targets are a valuable resource for treatment of SARS-CoV-2 viral infection. Genome-wide association studies have identified risk loci associated with COVID-19, but many loci are associated with comorbidities and are not specific to host–virus interactions. Here, we identify and experimentally validate a link between reduced expression of EXOSC2 and reduced SARS-CoV-2 replication. EXOSC2 was one of the 332 host proteins examined, all of which interact directly with SARS-CoV-2 proteins. Aggregating COVID-19 genome-wide association studies statistics for gene-specific eQTLs revealed an association between increased expression of EXOSC2 and higher risk of clinical COVID-19. EXOSC2 interacts with Nsp8 which forms part of the viral RNA polymerase. EXOSC2 is a component of the RNA exosome, and here, LC-MS/MS analysis of protein pulldowns demonstrated interaction between the SARS-CoV-2 RNA polymerase and most of the human RNA exosome components. CRISPR/Cas9 introduction of nonsense mutations within EXOSC2 in Calu-3 cells reduced EXOSC2 protein expression and impeded SARS-CoV-2 replication without impacting cellular viability. Targeted depletion of EXOSC2 may be a safe and effective strategy to protect against clinical COVID-19.

ORCID iDs

Moll, Tobias, Odon, Valerie ORCID logoORCID: https://orcid.org/0000-0002-2811-6916, Harvey, Calum, Collins, Mark O, Peden, Andrew, Franklin, John, Graves, Emily, Marshall, Jack NG, dos Santos Souza, Cleide, Zhang, Sai, Castelli, Lydia, Hautbergue, Guillaume, Azzouz, Mimoun, Gordon, David, Krogan, Nevan, Ferraiuolo, Laura, Snyder, Michael P, Shaw, Pamela J, Rehwinkel, Jan and Cooper-Knock, Johnathan;
CORE (COnnecting REpositories)